| Progyny, Inc. |
Director |
Common Stock |
228K |
$7.28M |
$31.95 |
May 23, 2024 |
Indirect |
| Vera Therapeutics, Inc. |
Director |
Class A Common Stock |
132K |
$6.52M |
$49.54 |
Oct 28, 2024 |
Direct |
| Kyverna Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
736K |
$1.55M |
$2.11 |
May 29, 2025 |
Indirect |
| Progyny, Inc. |
Director |
Common Stock |
43.4K |
$1.39M |
$31.95 |
May 23, 2024 |
Direct |
| Progyny, Inc. |
Director |
Stock Option (Right to Buy) |
26.9K |
$537K |
$19.93 |
May 23, 2024 |
Direct |
| Vera Therapeutics, Inc. |
Director |
Class A Common Stock |
4.01K |
$199K |
$49.54 |
Oct 28, 2024 |
Indirect |
| Atara Biotherapeutics, Inc. |
Director |
Common Stock |
116K |
$45K |
$0.39 |
May 31, 2023 |
Direct |
| Kyverna Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
16.6K |
$35.1K |
$2.11 |
May 29, 2025 |
Direct |
| Atara Biotherapeutics, Inc. |
Director |
Common Stock |
197 |
$77.00 |
$0.39 |
May 31, 2023 |
Indirect |
| ACELYRIN, Inc. |
Director |
Common Stock |
0 |
$0 |
$2.45 |
May 21, 2025 |
Direct |
| ACELYRIN, Inc. |
Director |
Common Stock |
0 |
$0 |
$2.45 |
May 21, 2025 |
Indirect |
| Atara Biotherapeutics, Inc. |
Director |
Non-Qualified Stock Option (Right to Buy) |
79.5K |
|
|
May 31, 2023 |
Direct |
| Kyverna Therapeutics, Inc. |
Director, 10%+ Owner |
Stock Option (right to buy) |
65.4K |
|
|
May 29, 2025 |
Direct |
| Sagimet Biosciences Inc. |
Director |
Stock Option (Right to Buy) |
32.3K |
|
|
Jun 9, 2025 |
Direct |
| Vera Therapeutics, Inc. |
Director |
Stock Option (right to buy) |
14K |
|
|
May 14, 2025 |
Direct |
| ACELYRIN, Inc. |
Director |
Director Stock Option (right to buy) |
0 |
|
|
May 21, 2025 |
Direct |